Ticker

Analysis demonstrates statistically significant reduction in the severity of surgical wound infections, with potential to lower hospital resource utilization following abdominal colorectal surgery PETACH TIKVA, Israel, April 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment…

BeOne Medicines (NASDAQ: ONC - Get Free Report) and PolyPid (NASDAQ: PYPD - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk. Volatility and Risk BeOne Medicines has a beta of

Analysis demonstrates D-PLEX₁₀₀ prolonged delivery mechanism ability to deliver continuous release of doxycycline for 30 days at the surgical incision site Analysis demonstrates D-PLEX₁₀₀ prolonged delivery mechanism ability to deliver continuous release of doxycycline for 30 days at the surgical incision site

PolyPid Ltd. (NASDAQ: PYPD - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average twelve-month price objective among

PolyPid Ltd. (NASDAQ: PYPD - Get Free Report)'s share price shot up 3.3% on Thursday. The company traded as high as $4.37 and last traded at $4.37. 13,903 shares were traded during trading, a decline of 75% from the average session volume of 56,428 shares. The stock had previously closed at $4.23. Wall Street Analyst